Neil Ahluwalia

Medical Director
Vertex Pharmaceuticals Incorporated

Poster(s):

• (163) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and ≥1 F508del allele: 96-week interim results from an open-label extension study
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (169) A Phase 4, Fully Decentralized Clinical Trial to Evaluate Physical Activity and Cough Frequency in Patients with Cystic Fibrosis Using Wearable Technology
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (170) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (185) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (693) A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 2 Through 5 Years of Age with Cystic Fibrosis and at Least One F508del Allele
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET